Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.  Cumulative safety data for STELARA™ (up to 18 months) based on pooled analyses of one Phase 2 and two Phase 3 clinical trials will also be presented.

"These data underscore our commitment to advancing the understanding and treatment of moderate to severe plaque psoriasis," said Dr. Thomas F. Schaible, Vice President, Medical Affairs, Centocor Ortho Biotech Inc. "We are pleased to be in a position to share these findings with the medical community at this year's AAD annual meeting, as the only company to offer two biologic options for the management of this chronic disease."

Data being presented as electronic posters include:

  • The ustekinumab safety experience in patients with moderate-to-severe psoriasis: Results from pooled analyses of Phase 2 and Phase 3 clinical trial data (Abstract P3336)

Authors: K. Gordon, North Shore University Health Systems, Skokie, IL; C. Leonardi, Center Dermatology, St. Louis, MO; K. Reich, Dermatologikum Hamburg, Hamburg, Germany; N. Yeilding, Centocor Research & Development, Malvern, PA

  • Ustekinumab treatment in patients with moderate-to-severe psoriasis who are non-responders to etanercept: Results from a Phase 3 clinical trial (Abstract P3357)

Authors: C. E. M. Griffiths, University of Manchester, United Kingdom; A. Menter, Baylor University Medical Center, Dallas, TX; B. Strober, New York University School of Medicine, New York, NY; N. Yeilding, Centocor Research & Development, Malvern, PA

  • Efficacy and safety of infliximab therapy in plaque psoriasis patients previously treated with etanercept: Analysis of PSUNRISE (Abstract P3341)

Authors: A.B. Gottlieb, Tufts Medical Center, Boston, MA; J. Wang, Johnson & Johnson Pharmaceutical Research & Development, Horsham, PA; M. Chevrier, Centocor Ortho Biotech Services, Horsham, PA; R. Kalb, SUNY at Buffalo School of Medicine, Buffalo, NY

Electronic poster exhibit viewing stations will be open during the course of the meeting at the Miami Beach Convention Center in Hall D.  


Centocor Ortho Biotech Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Mathematical modeling demonstrates efficacy of combinational drug therapy for breast cancer treatment